| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 1.11 | 27.6% |
| Total Income | 1.11 | 27.6% |
| Expenditure | 4.11 | 14.2% |
| PBT | — | |
| Net Profit | -2.98 | 10.8% |
| OPM | — | |
| NPM | — | |
| EPS | -0.35 | 50.0% |
Intelligent Bio Solutions Reports Q1 FY26 Revenue Up 28% Y-o-Y
04 May 2026 · 4 May, 7:27 am
Summary
Intelligent Bio Solutions Inc. announced its financial results for the fiscal first quarter ended September 30, 2025. The company reported record quarterly revenue of $1.11 million, driven by accelerating cartridge sales and strategic partnerships. Gross profit margins increased by 690 basis points year-over-year to 46.6%. The company secured a major contract with a London public transport operator and expanded its product portfolio with the addition of the SmarTest® Patch.
Key Highlights
- 1
Intelligent Bio Solutions reported a record quarterly revenue of $1.11 million, representing a 28% increase year-over-year.
- 2
The company's revenue increased by 32% sequentially from the fiscal fourth quarter 2025.
- 3
Cartridge sales of $640,300 represented 57.59% of total revenue, up from 51.1% in the fiscal first quarter of 2025.
- 4
Gross profit margins increased to 46.6% from 39.68% in the fiscal first quarter of 2025.
- 5
The company added 33 new customer accounts during the quarter, bringing the total number of active accounts to 492 across 24+ countries.
- 6
A major contract was secured with a London public transport operator covering 14 operational sites and over 4,400 staff.
- 7
The product portfolio expanded with the addition of the SmarTest® Patch, an innovative 7-10 day continuous drug monitoring solution.
Management Comments
Harry Simeonidis
“Our first quarter results show accelerating momentum of our business model and the growing market adoption internationally of our non-invasive drug screening technology,” “We achieved record quarterly revenue of $1.11 million, representing our strongest quarter to date, with 32% growth sequentially and 28% year-over-year. This significant revenue increase, combined with expanding gross margins, validates our strategic focus on consumable cartridge sales and positions us well for sustained growth as we advance along the regulatory pathway toward planned FDA clearance and U.S. market entry.”
Spiro Sakiris
“As our first fiscal quarter results show, the financial discipline implemented throughout fiscal 2025 is now translating into meaningful margin expansion and operational leverage,” “We are seeing strong returns on strategic investments, with improved customer acquisition metrics and accelerating revenue per account. We believe that we are well positioned to capitalize on the growth opportunities ahead.”
Informational and educational content only. Not investment advice.